Figure 3 | Scientific Reports

Figure 3

From: Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level

Figure 3

Differential expression analysis for 26 cytokines and response status in the omalizumab group. Shows the differential expression between omalizumab responders and non-responders from limma analysis adjusted for pre-treatment annualized exacerbation rate. Cytokines with raw P-value < 0.05 were considered statistically significant. Effect sizes are presented as log2 of fold change where positive (negative) values indicate up-regulation in responders (non-responders). The vertical dashed line represents no difference. The horizontal dashed line represents P-value < 0.05. Green dot indicates levels of the cytokine are higher in responders; Gray dot “None” indicates levels of that cytokine are not different between responders and nonresponders.

Back to article page